Brand Reynolds
Nurse Practitioner · Tooele, UTNPI 1154325991
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 80.9% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2022 at $5,533 and has fallen 86.6% since, to $742 in 2025. Among nurse practitioner clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 171 payments — averaging $71.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$10K
- Novo Nordisk$698
- Abbott$523
- AstraZeneca$140
- Amgen$117
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$80
- plus $783 from 21 others
What the payments were for
- Speaking & faculty fees$6,60054%
- Travel & lodging$2,56521%
- Food & beverage$3,06425%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 43 | $9,908 |
| Novo Nordisk | 45 | $698 |
| Abbott | 16 | $523 |
| AstraZeneca | 9 | $140 |
| Amgen | 7 | $117 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $80 |
| Lilly USA, LLC | 6 | $78 |
| Antares Pharma, Inc. | 2 | $73 |
| Pfizer | 5 | $66 |
| Bayer | 4 | $62 |
| Ironshore Pharmaceuticals Inc. | 4 | $59 |
| Regeneron Healthcare Solutions, Inc. | 3 | $56 |
| Vertex | 2 | $46 |
| Alkermes, Inc. | 3 | $43 |
| Lundbeck LLC | 2 | $36 |
| Boehringer Ingelheim | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Inspire Medical Systems, Inc. | 1 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $25 |
| Halozyme Inc | 1 | $23 |
| Lucid Diagnostics Inc. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Vivus LLC | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Medtronic | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$9,100
- Wegovy$244
- FREESTYLE LIBRE 3$108
How this compares
$12,248 in reported general payments places this provider in the 95th percentile of 979 nurse practitioner providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 56 | $66,100 |
| Austedo XrDeutetrabenazine | 12 | $57,631 |
| MounjaroTirzepatide | 42 | $45,664 |
| TrulicityDulaglutide | 47 | $45,411 |
| XareltoRivaroxaban | 32 | $34,077 |
| JardianceEmpagliflozin | 41 | $33,839 |
| OzempicSemaglutide | 22 | $27,732 |
| FarxigaDapagliflozin Propanediol | 13 | $20,129 |
| JanuviaSitagliptin Phosphate | 17 | $11,405 |
| BelsomraSuvorexant | 18 | $11,346 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $10,396 |
| DapagliflozinDapagliflozin Propanediol | 14 | $8,957 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 31 | $2,946 |
| Fenofibrate | 12 | $2,860 |
| Gabapentin | 168 | $2,584 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $78 | $91,07589 claims |
| PfizerEliquis | $66 | $66,10056 claims |
| Boehringer IngelheimJardiance | $34 | $33,83941 claims |
| Novo NordiskOzempic | $698 | $27,73222 claims |
| AstraZenecaFarxiga | $140 | $20,12913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 979 nurse practitioner providers in Utah.
Other nurse practitioner in Tooele
- David GambleAmerican Fork$836K
- Julia BattenSalt Lake City$223K
- Stacie EganOgden$170K
- Traci AndreasonLehi$161K
- Geoffrey OsmondDraper$62K
- Trenton GraySouth Salt Lake$40K
- Kelsey FurrWest Jordan$21K
- Merin KinikiniSalt Lake City$19K
- Lynn LarsenOgden$16K
- Phillip BowmanSalt Lake City$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.